Business Context and Reporting Period
Envoy Medical, Inc. (formerly Anzu Special Acquisition Corp I) filed this Form 8-K dated September 29, 2023. The filing reports completion of the business combination with Envoy Medical Corporation on September 29, 2023, pursuant to the Business Combination Agreement dated April 17, 2023, as amended.
Following the transaction, the company expects its Class A common stock and warrants to trade on Nasdaq under the symbols COCH and COCHW, respectively, beginning October 2, 2023.
Key Financial and Capital Markets Information
- Approximately 55% of Anzu’s Class A common stock, or 2,386,294 shares, was validly submitted for redemption.
- The redemption price was approximately $10.46 per share, representing approximately $25.0 million in aggregate redemptions as of September 27, 2023.
- The filing does not provide revenue, profit, operating cash flow, margins, total debt, or post-closing liquidity balances.
- Under the Forward Purchase Agreement with Meteora-related entities, the company paid the required prepayment amount directly from the trust account on September 29, 2023.
- The company also transferred 8,512 shares of Class A common stock to the seller as share consideration.
Material Changes Versus the Prior Comparable Period
This filing primarily reports a transformational corporate transaction rather than periodic operating results. Anzu completed its business combination, changed its name to Envoy Medical, Inc., and transitioned toward operating as a medical technology company. No comparable-period financial results are presented.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no quantitative revenue, earnings, cash flow, or operating guidance.
- The seller may conduct shortfall sales until gross proceeds reach $44,505. The company is entitled to retain 50% of that amount, with the seller paying the remaining 50% at the specified settlement date.
- The seller may, at its discretion, request warrants covering up to the difference between 4,300,000 shares and the number of shares specified in the applicable pricing notice. These warrants would have a reset-price exercise price, expire June 30, 2024, and generally would not permit cashless exercise or net share settlement.
- The company and seller waived the requirement to file a resale registration statement within 45 days after closing for specified recycled shares, shortfall-sale shares, share consideration, and related warrants.
- The seller waived redemption rights for the recycled shares. The filing states that this may have reduced the number of shares redeemed and could affect market perceptions of the transaction.
Most Important Facts for Investors to Verify
- Final post-transaction share count, cash balance, and trust-account proceeds after redemptions and transaction payments.
- The amount paid under the Forward Purchase Agreement and any remaining obligations, shortfall sales, or warrants.
- The actual Nasdaq commencement date and trading performance of COCH and COCHW.
- Envoy Medical’s subsequent financial statements, operating results, liquidity runway, debt, and commercialization plans.
- Any resale registration statements, warrant issuances, dilution, or other equity transactions arising from the Forward Purchase Agreement.